[1] D. Ricard, A. Idbaih, F. Ducray, M. Lahutte, K. Hoang-Xuan, and J.-Y. Delattre, “Primary brain tumours in adults,” Lancet, vol. 379, no. 9830, pp. 1984–1996, May 2012, doi: 10.1016/S0140-6736(11)61346-9.
[2] B. K. Shah, A. Bista, and S. Sharma, “Survival Trends in Elderly Patients with Glioblastoma in the United States: a Population-based Study,” Anticancer Res., vol. 36, no. 9, pp. 4883–4886, 2016, doi: 10.21873/anticanres.11052.
[3] R. Stupp et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl. J. Med., vol. 352, no. 10, pp. 987–996, Mar. 2005, doi: 10.1056/NEJMoa043330.
[4] M. Weller et al., “European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas,” Lancet Oncol., vol. 18, no. 6, pp. e315–e329, 2017, doi: 10.1016/S1470-2045(17)30194-8.
[5] Q. T. Ostrom, H. Gittleman, G. Truitt, A. Boscia, C. Kruchko, and J. S. Barnholtz-Sloan, “CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015,” Neuro-oncology, vol. 20, no. suppl_4, pp. iv1–iv86, 01 2018, doi: 10.1093/neuonc/noy131.
[6] C. F. Lorimer, F. Saran, A. J. Chalmers, and J. Brock, “Glioblastoma in the elderly - How do we choose who to treat?,” J Geriatr Oncol, vol. 7, no. 6, pp. 453–456, 2016, doi: 10.1016/j.jgo.2016.07.005.
[7] S. Hoffe and L. Balducci, “Cancer and age: general considerations,” Clin. Geriatr. Med., vol. 28, no. 1, pp. 1–18, Feb. 2012, doi: 10.1016/j.cger.2011.09.001.
[8] J. G. Scott et al., “Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older,” Cancer, vol. 118, no. 22, pp. 5595–5600, Nov. 2012, doi: 10.1002/cncr.27570.
[9] R. Rahman et al., “Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation,” J. Neurooncol., vol. 124, no. 1, pp. 137–146, Aug. 2015, doi: 10.1007/s11060-015-1820-3.
[10] M. E. Hegi et al., “MGMT gene silencing and benefit from temozolomide in glioblastoma,” N. Engl. J. Med., vol. 352, no. 10, pp. 997–1003, Mar. 2005, doi: 10.1056/NEJMoa043331.
[11] E. R. Gerstner, S. Yip, D. L. Wang, D. N. Louis, A. J. Iafrate, and T. T. Batchelor, “Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma,” Neurology, vol. 73, no. 18, pp. 1509–1510, Nov. 2009, doi: 10.1212/WNL.0b013e3181bf9907.
[12] M. E. Hegi et al., “MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials,” Clin. Cancer Res., vol. 25, no. 6, pp. 1809–1816, 15 2019, doi: 10.1158/1078-0432.CCR-18-3181.
[13] J. T. Jordan, E. R. Gerstner, T. T. Batchelor, D. P. Cahill, and S. R. Plotkin, “Glioblastoma care in the elderly,” Cancer, vol. 122, no. 2, pp. 189–197, Jan. 2016, doi: 10.1002/cncr.29742.
[14] A. Asmaa et al., “Management of elderly patients with glioblastoma-multiforme-a systematic review,” Br J Radiol, vol. 91, no. 1088, p. 20170271, 2018, doi: 10.1259/bjr.20170271.
[15] G. Minniti, G. Lombardi, and S. Paolini, “Glioblastoma in Elderly Patients: Current Management and Future Perspectives,” Cancers, vol. 11, no. 3, Mar. 2019, doi: 10.3390/cancers11030336.
[16] A. Fiorentino et al., “Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials?,” Am. J. Clin. Oncol., vol. 38, no. 1, pp. 23–27, Feb. 2015, doi: 10.1097/COC.0b013e3182868ea2.
[17] R. Stupp et al., “Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial,” Lancet Oncol., vol. 10, no. 5, pp. 459–466, May 2009, doi: 10.1016/S1470-2045(09)70025-7.
[18] C. Gzell, H. Wheeler, L. Guo, M. Kastelan, and M. Back, “Elderly patients aged 65-75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide,” J. Neurooncol., vol. 119, no. 1, pp. 187–196, Aug. 2014, doi: 10.1007/s11060-014-1472-8.
[19] E. Franceschi et al., “Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study,” J. Neurooncol., vol. 128, no. 1, pp. 157–162, 2016, doi: 10.1007/s11060-016-2093-1.
[20] G. Minniti et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients,” J Neurooncol, vol. 88, no. 1, pp. 97–103, May 2008, doi: 10.1007/s11060-008-9538-0.
[21] C. A. Barker et al., “Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma,” J Neurooncol, vol. 109, no. 2, pp. 391–397, Sep. 2012, doi: 10.1007/s11060-012-0906-4.
[22] J. Biau et al., “Radiotherapy plus temozolomide in elderly patients with glioblastoma: a ‘real-life’ report,” Radiat Oncol, vol. 12, no. 1, p. 197, Dec. 2017, doi: 10.1186/s13014-017-0929-2.
[23] C. N. Chang-Halpenny, J. Yeh, and W. W. Lien, “Elderly patients with glioblastoma multiforme treated with concurrent temozolomide and standard- versus abbreviated-course radiotherapy,” Perm J, vol. 19, no. 1, pp. 15–20, 2015, doi: 10.7812/TPP/14-083.
[24] S. E. Combs et al., “Postoperative Treatment of Primary Glioblastoma Multiforme With Radiation and Concomitant Temozolomide in Elderly Patients,” International Journal of Radiation Oncology*Biology*Physics, vol. 70, no. 4, pp. 987–992, Mar. 2008, doi: 10.1016/j.ijrobp.2007.07.2368.
[25] J. Gerstein et al., “Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma,” Radiotherapy and Oncology, vol. 97, no. 3, pp. 382–386, Dec. 2010, doi: 10.1016/j.radonc.2010.06.014.
[26] C. Hanna et al., “Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis,” Cochrane Database Syst Rev, vol. 3, p. CD013261, Mar. 2020, doi: 10.1002/14651858.CD013261.pub2.
[27] F. Keime-Guibert et al., “Radiotherapy for glioblastoma in the elderly,” N. Engl. J. Med., vol. 356, no. 15, pp. 1527–1535, Apr. 2007, doi: 10.1056/NEJMoa065901.
[28] A. Malmström et al., “Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial,” Lancet Oncol., vol. 13, no. 9, pp. 916–926, Sep. 2012, doi: 10.1016/S1470-2045(12)70265-6.
[29] W. Roa et al., “International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme,” J. Clin. Oncol., vol. 33, no. 35, pp. 4145–4150, Dec. 2015, doi: 10.1200/JCO.2015.62.6606.
[30] W. Roa et al., “Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial,” J. Clin. Oncol., vol. 22, no. 9, pp. 1583–1588, May 2004, doi: 10.1200/JCO.2004.06.082.
[31] N. D. Arvold et al., “Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients,” Int. J. Radiat. Oncol. Biol. Phys., vol. 92, no. 2, pp. 384–389, Jun. 2015, doi: 10.1016/j.ijrobp.2015.01.017.
[32] G. Minniti et al., “Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis,” Int. J. Radiat. Oncol. Biol. Phys., vol. 91, no. 1, pp. 109–115, Jan. 2015, doi: 10.1016/j.ijrobp.2014.09.013.
[33] J. R. Perry et al., “Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma,” N. Engl. J. Med., vol. 376, no. 11, pp. 1027–1037, 16 2017, doi: 10.1056/NEJMoa1611977.
[34] A. Laprie et al., “Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging,” BMC Cancer, vol. 19, no. 1, p. 167, Feb. 2019, doi: 10.1186/s12885-019-5317-x.
[35] E. P. Sulman et al., “Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline,” J. Clin. Oncol., vol. 35, no. 3, pp. 361–369, Jan. 2017, doi: 10.1200/JCO.2016.70.7562.
[36] L. Feuvret, D. Antoni, J. Biau, G. Truc, G. Noël, and J.-J. Mazeron, “[Guidelines for the radiotherapy of gliomas],” Cancer Radiother, vol. 20 Suppl, pp. S69-79, Sep. 2016, doi: 10.1016/j.canrad.2016.07.008.
[37] N. Verma, M. C. Cowperthwaite, M. G. Burnett, and M. K. Markey, “Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies,” Neuro Oncol, vol. 15, no. 5, pp. 515–534, May 2013, doi: 10.1093/neuonc/nos307.
[38] U. Herrlinger et al., “Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial,” Lancet, vol. 393, no. 10172, pp. 678–688, 16 2019, doi: 10.1016/S0140-6736(18)31791-4.
[39] M. R. Gilbert et al., “Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial,” J. Clin. Oncol., vol. 31, no. 32, pp. 4085–4091, Nov. 2013, doi: 10.1200/JCO.2013.49.6968.
[40] F. S. Lieberman et al., “Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420,” Int. J. Radiat. Oncol. Biol. Phys., vol. 103, no. 4, pp. 878–886, 15 2019, doi: 10.1016/j.ijrobp.2018.11.008.
[41] D. T. Blumenthal et al., “Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG,” Neuro-oncology, vol. 19, no. 8, pp. 1119–1126, Aug. 2017, doi: 10.1093/neuonc/nox025.
[42] M. R. Gilbert et al., “A randomized trial of bevacizumab for newly diagnosed glioblastoma,” N. Engl. J. Med., vol. 370, no. 8, pp. 699–708, Feb. 2014, doi: 10.1056/NEJMoa1308573.
[43] O. L. Chinot et al., “Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma,” N. Engl. J. Med., vol. 370, no. 8, pp. 709–722, Feb. 2014, doi: 10.1056/NEJMoa1308345.
[44] R. Stupp et al., “Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial,” Lancet Oncol., vol. 15, no. 10, pp. 1100–1108, Sep. 2014, doi: 10.1016/S1470-2045(14)70379-1.
[45] M. Weller et al., “Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial,” Lancet Oncol., vol. 18, no. 10, pp. 1373–1385, 2017, doi: 10.1016/S1470-2045(17)30517-X.
[46] M. Lim, Y. Xia, C. Bettegowda, and M. Weller, “Current state of immunotherapy for glioblastoma,” Nat Rev Clin Oncol, vol. 15, no. 7, pp. 422–442, 2018, doi: 10.1038/s41571-018-0003-5.
[47] R. Stupp et al., “Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial,” JAMA, vol. 318, no. 23, pp. 2306–2316, 19 2017, doi: 10.1001/jama.2017.18718.
[48] W. Wick et al., “Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial,” Lancet Oncol., vol. 13, no. 7, pp. 707–715, Jul. 2012, doi: 10.1016/S1470-2045(12)70164-X.
[49] J. Gállego Pérez-Larraya et al., “Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial,” J. Clin. Oncol., vol. 29, no. 22, pp. 3050–3055, Aug. 2011, doi: 10.1200/JCO.2011.34.8086.